Article Text

Download PDFPDF
Association of HLA-DM polymorphism with the production of antiphospholipid antibodies
  1. M L Sanchez1,
  2. K Katsumata1,
  3. T Atsumi1,
  4. F I Romero1,
  5. M L Bertolaccini1,
  6. A Funke1,
  7. O Amengual1,
  8. E Kondeatis2,
  9. R W Vaughan2,
  10. A Cox3,
  11. G R V Hughes1,
  12. M A Khamashta1
  1. 1Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London SE1, UK
  2. 2Tissue Typing Department, Guy’s Hospital, London SE1, UK
  3. 3Institute for Cancer Studies, University of Sheffield Medical School, Sheffield, UK
  1. Correspondence to:
    M A Khamashta
    Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, SE1 7EH, UK; munther.khamashtakcl.ac.uk

Abstract

Objective: To investigate whether variation in the HLA-DM gene is important in producing a group of pathogenic autoantibodies—antiphospholipid antibodies (aPL)—on the basis that HLA class II restricted antigen presentation is involved in the production of aPL.

Methods: HLA-DMA and DMB polymorphisms were genotyped by polymerase chain reaction combined with restriction enzyme digestion in 51 white patients with primary antiphospholipid syndrome (APS), 82 with systemic lupus erythematosus (SLE) (42 with APS and 40 without APS), and 109 healthy white controls. The association with the aPL profile was examined.

Results: The distribution of DMA alleles in APS patients and in patients with APS associated with SLE was significantly different from that in controls by 4×2 χ2 test with 3 degrees of freedom (p = 0.035 and 0.011, respectively), but it was not different between SLE patients without APS and controls. The allelic distribution of DMA was also different between patients with IgG class anticardiolipin antibody or those with lupus anticoagulant (LA) and controls (p = 0.012 and 0.007, respectively) and between patients with and without LA among SLE patients (p = 0.035). All these differences included the increase in DMA*0102 in the former groups.

Conclusions: The results suggest that HLA-DMA*0102 or its linked gene(s) form one of the genetic risks for the production of aPL.

  • aPL, antiphospholipid antibodies
  • APS, antiphospholipid syndrome
  • LA, lupus anticoagulant
  • RFLP, restriction fragment length polymorphism
  • anticardiolipin antibody
  • antiphospholipid antibody
  • antiphospholipid syndrome
  • HLA-DM
  • lupus anticoagulant

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes